LF control probability vs number treatments and tests for community-wide triple-drug MDA and household-based strategies. by Callum Shaw (15628313)

“…<p>Control probability was the proportion of simulations in which mf prevalence decreased from 2030 to 2035 and the household-based strategies offered testing to either 25% or 50% of households (HTA). …”

Viral decay dynamics affected by timing of ART initiation. by Brandon F. Keele (7450001)

Microorganisms. by Lucas Romann (14803595)

“…<div><p>Background</p><p>Blood cultures (BC) are critical for the diagnosis of bloodstream infections, pathogen identification, and resistance testing. Guidelines recommend a blood volume of 8–10 mL per bottle as lower volumes result in decreased sensitivity. …”

Flowchart of the BCs included into this study. by Lucas Romann (14803595)

“…<div><p>Background</p><p>Blood cultures (BC) are critical for the diagnosis of bloodstream infections, pathogen identification, and resistance testing. Guidelines recommend a blood volume of 8–10 mL per bottle as lower volumes result in decreased sensitivity. …”

General characteristics of studied sample. by Khalid Abdul Basit (15332672)

“…A total of 4250 participants were included in this combined analysis, 2515 from 2001–2002, 1377 from 2009–2010 and 358 from 2016–2017 survey year. …”

Delay in first phase viral decay kinetics when ART is started pre-peak. by Brandon F. Keele (7450001)

Code to generate Figure 3 from KDM1A paper by Jessica Chong (474458)

“…Additionally, as the specificity of the phenotype of interest increases, the proportion of individuals tested who have the phenotype (y-axis) naturally decreases, also resulting in increased power. A small decrease (60% to 50%) in the proportion of individuals who have the phenotype of interest can increase power more than sequencing 10,000 additional trios.…”

TLC photography of fungal extract. by Shivankar Agrawal (11565095)

Phases of the accumulation of RCVR during primary infection. by Brandon F. Keele (7450001)

The effectiveness of additional rounds of annual 3D-MDA starting in 2023 for three different levels of treatment coverage. by Callum Shaw (15628313)

The effectiveness of the household-based strategy, with different number of teams, treatment radii, and household test aims (HTA). by Callum Shaw (15628313)

Results of ABC fitting—transformed parameters. by Callum Shaw (15628313)

Fig 1 - by Khalid Abdul Basit (15332672)

No viral measurement predicts off-ART rebound or not in d3 or d4 ART RMs. by Brandon F. Keele (7450001)

Rebound kinetics and time to detection following ART discontinuation. by Brandon F. Keele (7450001)

Pre- and early post-ART viral dynamics. by Brandon F. Keele (7450001)

SIV CA-DNA, SIV CA-RNA, and IPDA levels prior to ART interruption using CA-DNA and RNA values and IPDA. by Brandon F. Keele (7450001)

Barcode assessment post rebound. by Brandon F. Keele (7450001)

Reactivation rates. by Brandon F. Keele (7450001)

Fig 1 - by Qiumeng Zhang (4184326)